Fatigue in patients with chronic inflammatory demyelinating polyneuropathy
https://doi.org/10.14412/2074-2711-2021-1-51-56
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a peripheral neuropathy, predominantly motor neuropathy, with a progressive or relapse-remitting course. Fatigue is a condition characterized by a physical or mental feeling of lack of energy or lack of motivation for action, which is often present in patients with CIDP.
Objective: to assess the severity of asthenia in CIDP patients.
Patients and methods. Examinations were made in 34 inpatients treated for documented CIDP that met the international European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria. A study group included patients with CIDP, whereas a comparison group consisted of volunteers without psychiatric illness, who were compensated for somatic diseases.
Results and discussion. In the patients with CIDP, the level of fatigue was found to be much higher than normal. Approximately half of the CIDP patients had obvious asthenia. However, the level of fatigue did not correlate with the severity of the course of CIDP.
Conclusion. The findings suggest that fatigue is important in patients with CIDP that should be taken into account in the treatment of these patients.
About the Authors
R. A. GapeshinRussian Federation
Roman Andreevich Gapeshin
6-8, Lev Tolstoy St., Saint Petersburg 197022
E. R. Barantsevich
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
D. I. Rudenko
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
5, Uchebnyi Lane, Saint Petersburg 194354
T. R. Stuchevskaya
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
5, Uchebnyi Lane, Saint Petersburg 194354
E. A. Gavrilova
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
M. S. Pushkaryov
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
A. A. Yakovlev
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
41, Kirochnaya St., Saint Petersburg 191015
A. V. Gavrichenko
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
A. G. Smochilin
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022
References
1. Khoo A, Frasca J, Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Biomark Res. 2019;7(1):1-8. doi: 10.1186/s40364-0190154-2
2. Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complicat. Sep-Oct 2016;30(7):1401-7. doi: 10.1016/j.jdiacomp.2016.05.007. Epub 2016 May 10.
3. Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-72. doi: 10.1159/000494291
4. Popova TE, Shnayder NA, Petrova MM, et al. Epidemiology of chronic inflammatory demyelinating polyneuropathy abroad and in Russia. Nervno-myshechnyye bolezni = Neuromuscular Diseases. 2015;5(2):10-5. doi: 10.17650/2222-8721-2015-5-2-10-15 (In Russ.).
5. Tursynov NI, Grigolashvili MA, Iluyshina NYu, et al. Modern aspects of diagnosis and treatment of chronic demyelinated polyneuropathies. Neyrokhirurgiya i nevrologiya Kazakhstana = Neurosurgery and Neurology of Kazahstan. 2016;3(44):38-45 (In Russ.).
6. Shchukin IA, Lebedeva AV, Chubykin VI, et al. Asthenia in patients with chronic neurological disorders. Klinitsist = The Clinician. 2013;7(2):64-72. doi: 10.17650/1818-83382013-2-64-72 (In Russ.).
7. Lawley A, Abbas A, Seri S, Rajabally YA. Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;62(2):226-32. doi: 10.1002/mus.26913
8. Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol. 2010;17(3):356-63. doi: 10.1111/j.1468-1331.2009.02930.x
9. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49(1):229-39. doi: 10.1212/wnl.49.1.229
10. Kleyweg RP, Meche FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength Guillain-Barre syndrome. Muscle Nerve. 1991 Nov;14(11):1103-9. doi: 10.1002/mus.880141111
11. Alabdali M, Abraham A, Alsulaiman A, et al. Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. J Neurol Sci. 2017 Jan 15;372:223-7. doi: 10.1016/j.jns.2016.11.056. Epub 2016 Nov 23.
12. Merkies ISJ, Kieseier BC. Fatigue, pain, anxiety and depression in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. 2016;75(3-4):199-206. doi: 10.1159/000445347
13. Gavrilov YuV, Shkilnyuk GG, Valko PO, et al. Validation of the Russian Version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients. Acta Neurol Scand. 2018 Nov;138(5):408-416. doi: 10.1111/ane.12993. Epub 2018 Jul 9.
14. Chaudhuri A, Behan P. Fatigue in neurological disorders. Lancet. 2004 Mar 20;363(9413):978-88. doi: 10.1016/S01406736(04)15794-2
15. Zwarts MJ, Bleijenberg G, van Engelen BGM. Clinical neurophysiology of fatigue. Clin Neurophysiol. 2008 Jan;119(1):2-10. doi: 10.1016/j.clinph.2007.09.126. Epub 2007 Nov 26.
16. Kent-Braun JA, Le Blanc R. Quantitation of Central Activation Failure During Maximal Volintary Contractions in Humans. Muscle Nerve. 1996 Jul;19(7):861-9. doi: 10.1002/(SICI)10974598(199607)19:7<861::AIDMUS8>3.0.CO;2-7
17. Garssen MPJ, Schillings ML, van Doorn PA, et al. Contributions of Central and Peripheral Factors to Residual Fatigue in Guillain-Barre Syndrome. Muscle Nerve. 2007 Jul;36(1):93-9. doi: 10.1002/mus.20739
18. Boukhris S, Magy L, Gallouedec G, et al. Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: A study of 11 cases. J Peripher Nerv Syst. 2005 Sep;10(3):329-37. doi: 10.1111/j.1085-9489.2005.10311.x
19. Westblad ME, Forsberg A, Press R. Disability and health status in patients with chronic inflammatory demyelinating polyneuropathy. Disabil Rehabil. 2009;31(9):720-5. doi: 10.1080/09638280802306497
20. Gable KL, Attarian H, Allen JA. Fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020 Dec;62(6):673-80. doi: 10.1002/mus.27038. Epub 2020 Aug 10.
21. Merkies IS, Schmitz PI, Samijn JP, et al. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 1999;53(8):1648-54. doi: 10.1212/WNL.53.8.1648
22. Li SH, Lloyd AR, Graham BM. Physical and mental fatigue across the menstrual cycle in women with and without generalized anxiety disorder. Horm Behav. 2020 Feb;118:104667. doi: 10.1016/j.yhbeh.2019.104667. Epub 2020 Jan 8.
23. Garssen MP, Bussmann JB, Schmitz PI, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barrе syndrome and CIDP. Neurology. 2004 Dec 28;63(12):2393-5. doi: 10.1212/01.wnl.0000148589.87107.9c
24. Markvardsen LK, Carstens A-KR, Knak KL, et al. Muscle Strenght and Aerobic Capacity in Patients with CIDP One Year after Participation in an Exercise Trial. J Neuromuscular Dis. 2019;6(1):93-7. doi: 10.3233/JND-180344
Review
For citations:
Gapeshin RA, Barantsevich ER, Rudenko DI, Stuchevskaya TR, Gavrilova EA, Pushkaryov MS, Yakovlev AA, Gavrichenko AV, Smochilin AG. Fatigue in patients with chronic inflammatory demyelinating polyneuropathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):51-56. https://doi.org/10.14412/2074-2711-2021-1-51-56